


NOTICE TO THE BAR
MULTICOUNTY LITIGATION –
DESIGNATION OF TAXOTERE® LITIGATION AS MCL

A previous Notice to the Bar requested comments on an application for multicounty litigation (MCL) designation of New Jersey state-court litigation alleging injuries resulting from use of the drug Taxotere® (docetaxel). This Notice is to advise that the Supreme Court, after considering the application and the comments received, has determined to designate all litigation involving such allegations of injuries from use of the drug Taxotere (docetaxel) as multicounty litigation. The Court has assigned this MCL to Middlesex County for centralized case management by Superior Court Judge James F. Hyland.

Published with this Notice is the Supreme Court's July 17, 2018 Order. This Order is posted in the Multicounty Litigation Center <http://www.njcourts.gov/attorneys/mcl/index/html> on the Judiciary's website (www.njcourts.gov). Judge Hyland's Initial Case Management Order will be posted in the Multicounty Litigation Center once issued.

Questions concerning this matter may be directed to Taironda E. Phoenix, Esq., Assistant Director, Civil Practice Division, Administrative Office of the Courts, Hughes Justice Complex, P. O. Box 981, Trenton, New Jersey 08625-0981; telephone: (609) 815-2900 ext. 54901; e-mail address: taironda.phoenix@njcourts.gov.



Glenn A. Grant, J.A.D.
Acting Administrative Director of the Courts

Dated: August 15, 2018

SUPREME COURT OF NEW JERSEY

On application made pursuant to Rule 4:38A and the Multicounty Litigation Guidelines promulgated by Directive # 08-12 in accordance with that Rule, it is hereby ORDERED that all pending and future New Jersey state court actions against Sanofi U.S. Services, Inc., sanofi-aventis U.S. LLC, Accord Healthcare, Inc., Sandoz Inc., Hospira Worldwide LLC f/k/a Hospira Worldwide, Inc., Pfizer Inc., Actavis LLC f/k/a Actavis, Inc. and Sun Pharmaceutical Industries, Inc. f/k/a Caraco Pharmaceutical Laboratories, Ltd., alleging injuries as a result of use of the drug Taxotere (docetaxel) be designated as multicounty litigation ("MCL") for centralized management purposes; and

It is FURTHER ORDERED that any and all such complaints that have been filed in the various counties and that are under or are awaiting case management and/or discovery shall be transferred from the county of venue to the Superior Court, Law Division, Middlesex County and that, pursuant to N.J. Const. (1947), Art.VI, sec.2, par.3, the provisions of Rule 4:3-2 governing venue in the Superior Court are supplemented and relaxed so that all future such complaints, no matter where they might be venued, shall be filed in Middlesex County; and

It is FURTHER ORDERED that Superior Court Judge James F. Hyland shall oversee management and trial issues for such cases and may, in his discretion, return such cases to the original county of venue for disposition, and

It is FURTHER ORDERED that no Mediator or Master may be appointed in this litigation without the express prior approval of the Chief Justice.

For the Court



Chief Justice

Dated: July 17, 2018